Novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer

UroToday shared a post on X:           .

“The EvoPAR-Prostate 01 Trial: Novel PARP inhibitor saruparib in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Neeraj Agarwal from Huntsman Cancer Institute and Zach Klaassen from Georgia Cancer Center discuss this new PARP inhibitor combined with ARPI in both biomarker-positive and negative populations.”

Proceed to the video.
Source: UroToday/X